BRPI0709266B8 - 5-(hidroximetileno e aminometileno) pirimidinas substituídas e composição farmacêutica que as compreende - Google Patents

5-(hidroximetileno e aminometileno) pirimidinas substituídas e composição farmacêutica que as compreende

Info

Publication number
BRPI0709266B8
BRPI0709266B8 BRPI0709266A BRPI0709266A BRPI0709266B8 BR PI0709266 B8 BRPI0709266 B8 BR PI0709266B8 BR PI0709266 A BRPI0709266 A BR PI0709266A BR PI0709266 A BRPI0709266 A BR PI0709266A BR PI0709266 B8 BRPI0709266 B8 BR PI0709266B8
Authority
BR
Brazil
Prior art keywords
aminomethylene
hydroxymethylene
pharmaceutical composition
substituted pyrimidines
hiv
Prior art date
Application number
BRPI0709266A
Other languages
English (en)
Inventor
Antoine Schimitt Benoit
Isabelle Mordant Cêline
Emile Georges Guilllemont Jerôme
Original Assignee
Janssen R & D Ireland
Janssen Sciences Ireland Uc
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen R & D Ireland, Janssen Sciences Ireland Uc, Tibotec Pharm Ltd filed Critical Janssen R & D Ireland
Publication of BRPI0709266A2 publication Critical patent/BRPI0709266A2/pt
Publication of BRPI0709266B1 publication Critical patent/BRPI0709266B1/pt
Publication of BRPI0709266B8 publication Critical patent/BRPI0709266B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

5-(hidroximetileno e aminometileno)pirimidinas substituídas e composição farmacêutica contendo as mesmas. a presente invenção refere-se a derivados de 5-(hidroximetileno e aminometileno)pirimidina tendo propriedades de inibição de replicação de hiv (vírus da imunodeficiência humana), à preparação dos mesmos e a composições farmacêuticas compreendendo esses compostos.
BRPI0709266A 2006-03-30 2007-03-30 5-(hidroximetileno e aminometileno) pirimidinas substituídas e composição farmacêutica que as compreende BRPI0709266B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06112045 2006-03-30
EP06112045.7 2006-03-30
PCT/EP2007/053113 WO2007113256A1 (en) 2006-03-30 2007-03-30 Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines

Publications (3)

Publication Number Publication Date
BRPI0709266A2 BRPI0709266A2 (pt) 2011-06-28
BRPI0709266B1 BRPI0709266B1 (pt) 2020-09-29
BRPI0709266B8 true BRPI0709266B8 (pt) 2021-05-25

Family

ID=36808784

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0709266A BRPI0709266B8 (pt) 2006-03-30 2007-03-30 5-(hidroximetileno e aminometileno) pirimidinas substituídas e composição farmacêutica que as compreende

Country Status (18)

Country Link
US (1) US8163745B2 (pt)
EP (1) EP2004641B1 (pt)
JP (1) JP5070278B2 (pt)
KR (1) KR20080104040A (pt)
CN (1) CN101410394B (pt)
AT (1) ATE482953T1 (pt)
AU (1) AU2007233739B2 (pt)
BR (1) BRPI0709266B8 (pt)
CA (1) CA2645959C (pt)
DE (1) DE602007009508D1 (pt)
DK (1) DK2004641T3 (pt)
ES (1) ES2353725T3 (pt)
HR (1) HRP20100696T1 (pt)
IL (1) IL193725A (pt)
MX (1) MX2008012577A (pt)
RU (1) RU2452737C2 (pt)
SI (1) SI2004641T1 (pt)
WO (1) WO2007113256A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2398768C2 (ru) * 2005-02-18 2010-09-10 Тиботек Фармасьютикалз Лтд. Ингибирующие вич производные 2-(4-цианофениламино)-пиримидин-оксида
AU2007341227C1 (en) * 2006-12-29 2013-08-29 Janssen Sciences Ireland Uc HIV inhibiting 6-substituted pyrimidines
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
KR101956261B1 (ko) 2008-05-21 2019-03-08 어리어드 파마슈티칼스, 인코포레이티드 키나아제 억제제로서 포스포러스 유도체
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR101892989B1 (ko) 2008-06-27 2018-08-30 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
JP6068340B2 (ja) 2010-08-10 2017-01-25 セルジーン アヴィロミクス リサーチ， インコーポレイテッド Ｂｔｋ阻害剤のベシル酸塩
EP2635284B1 (en) 2010-11-01 2019-12-18 Celgene CAR LLC Heterocyclic compounds and uses thereof
JP5956999B2 (ja) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
JP5957003B2 (ja) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 変異体選択的ｅｇｆｒ阻害剤およびその使用
JP5999177B2 (ja) 2011-05-04 2016-09-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
CN102260215A (zh) * 2011-05-13 2011-11-30 复旦大学 一种二芳基嘧啶类衍生物及其制备方法和用途
TW201325593A (zh) 2011-10-28 2013-07-01 Celgene Avilomics Res Inc 治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法
CA2866857C (en) 2012-03-15 2021-03-09 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
KR102081042B1 (ko) 2012-03-15 2020-02-26 셀젠 카르 엘엘씨 상피 성장 인자 수용체 키나제 억제제의 고체 형태
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
EP2935226A4 (en) 2012-12-21 2016-11-02 Celgene Avilomics Res Inc HETEROARYL COMPOUNDS AND USES THEREOF
TW201446745A (zh) 2013-02-08 2014-12-16 Celgene Avilomics Res Inc Ｅｒｋ抑制劑及其用途
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
CN103483272B (zh) * 2013-09-29 2015-10-21 山东大学 间二芳烃-多取代嘧啶类衍生物及其制备方法与应用
RU2547844C1 (ru) * 2013-10-29 2015-04-10 Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук Способ получения 5-(гет)арил-4-(2-тиенил)-2-(тио)морфолилпиримидина
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
CZ154398A3 (cs) 1995-11-23 1998-08-12 Janssen Pharmaceutica N.V. Pevné směsi cyklodextrinů připravené vytlačováním taveniny
DK0945443T3 (da) 1998-03-27 2003-06-02 Janssen Pharmaceutica Nv HIV-hæmmende pyrimidinderivater
UA70966C2 (uk) 1998-11-10 2004-11-15 Янссен Фармацевтика Н.В. Піримідини, що інгібують реплікацію віл
JP5230050B2 (ja) * 2000-05-08 2013-07-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ複製阻害剤
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
BRPI0406809A (pt) * 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
US20070021449A1 (en) * 2003-02-07 2007-01-25 Jan Heeres Pyrimidine derivatives for the prevention of hiv infection
BRPI0515935B8 (pt) * 2004-09-30 2021-05-25 Janssen Sciences Ireland Uc pirimidinas heterociclil- ou 5-carbo substituídas para inibição de hiv, e composição farmacêutica

Also Published As

Publication number Publication date
EP2004641A1 (en) 2008-12-24
HRP20100696T1 (hr) 2011-01-31
CA2645959A1 (en) 2007-10-11
EP2004641B1 (en) 2010-09-29
KR20080104040A (ko) 2008-11-28
US20100234375A1 (en) 2010-09-16
CN101410394A (zh) 2009-04-15
DK2004641T3 (da) 2011-01-24
CN101410394B (zh) 2012-02-08
DE602007009508D1 (de) 2010-11-11
JP5070278B2 (ja) 2012-11-07
JP2009531395A (ja) 2009-09-03
ATE482953T1 (de) 2010-10-15
ES2353725T3 (es) 2011-03-04
WO2007113256A1 (en) 2007-10-11
MX2008012577A (es) 2008-10-10
IL193725A0 (en) 2009-05-04
BRPI0709266A2 (pt) 2011-06-28
CA2645959C (en) 2016-05-17
AU2007233739A1 (en) 2007-10-11
RU2452737C2 (ru) 2012-06-10
SI2004641T1 (sl) 2011-02-28
RU2008143018A (ru) 2010-05-10
BRPI0709266B1 (pt) 2020-09-29
AU2007233739B2 (en) 2013-01-17
IL193725A (en) 2014-11-30
US8163745B2 (en) 2012-04-24

Similar Documents

Publication Publication Date Title
BRPI0709266B8 (pt) 5-(hidroximetileno e aminometileno) pirimidinas substituídas e composição farmacêutica que as compreende
MX2008012576A (es) Pirimidinas 5-amido sustituidas inhibidoras del virus de inmunodeficiencia humana.
EA201200631A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
BRPI0720270B8 (pt) compostos 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina, composição e forma de dosagem sólida
BRPI0915084B8 (pt) composto, e, composição farmacêutica
WO2008127364A3 (en) Antiviral compounds and use thereof
HN2009001145A (es) Compuestos y composiciones como inhibidores de proteina quinasa
WO2008031556A3 (en) 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
CL2007002128A1 (es) Derivados de n'-ciano-n-halogenoalquil-imidamida; procedimiento para la preparacion de dicho compuesto; composiciones farmaceuticas que lo contienen; y uso del compuesto para combatir parasitos animales.
HN2009000499A (es) 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil} amino)3-fluorofenoxi]-n-metilpiridina-2- carboxamida monohidrato.
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
MY148634A (en) Pyridazinone derivatives
WO2008089105A3 (en) Antiviral nucleoside analogs
UY29266A1 (es) Compuestos de piridazinona
TW200621313A (en) Pharmaceutical compositions
CL2007002836A1 (es) Compuestos derivados de 1,3,5-triazina o pirimidina, inhibidores de quinasa; composicion farmaceutica; y uso para tratar una enfermedad mediada por quinasa, tal como cancer.
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
CR8824A (es) Derivados de 2-carbamida-4-feniltiazol, su preparacion y su aplicacion en terapeutica
CR11359A (es) Derivados de pirrolo (2,3-d) pirimidina como inhibidores de proteinas quinasa b
BRPI0818804A2 (pt) Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
MX2009005363A (es) Pirimidinas y su uso como antagonistas del receptor cxcr2.
TN2009000398A1 (en) 5,6-dihydro-1h-pyridin-2-one compounds
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
MA32776B1 (fr) Inhibiteurs de l'akt et de la p70 s6 kinase
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TIBOTEC PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/03/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.